Liraglutide injectable

Description

Liraglutide is a peptide-based GLP-1 (glucagon-like peptide-1) receptor agonist developed for the management of type 2 diabetes mellitus and weight control in clinically indicated cases. It is a long-acting analogue of the natural human GLP-1 hormone, designed to support glucose regulation and appetite control.

Mechanism of Action

Liraglutide works by activating GLP-1 receptors, which play a key role in metabolic regulation. Its effects include:

• Glucose-dependent stimulation of insulin secretion
• Suppression of excess glucagon release
• Slowing of gastric emptying
• Increased satiety and reduced appetite

Because its insulin-stimulating effect is glucose-dependent, the risk of hypoglycemia is low when used without insulin or sulfonylureas.

Intended Use

Liraglutide is prescribed for:

• Adults with type 2 diabetes, as monotherapy or in combination with other antidiabetic agents
• Adults with overweight or obesity, as part of a structured weight-management program

It is not indicated for type 1 diabetes and does not replace insulin.

Key Characteristics

• Class: GLP-1 receptor agonist
• Structure: Synthetic peptide (GLP-1 analogue)
• Administration: Subcutaneous injection
• Action profile: Long-acting, once-daily activity
• Hormonal activity: Non-androgenic, non-steroidal

Important Information

• Liraglutide requires a functioning pancreas to be effective
• Gastrointestinal side effects (such as nausea) may occur, especially during initiation
• Not suitable for individuals with certain endocrine conditions or a history of specific thyroid disorders

Notice

This product is a prescription medication. Use should be based on medical evaluation and supervised by a qualified healthcare professional. This description is provided for informational purposes only and does not replace professional medical advice.